Boehringer's Vargatef comes up one endpoint short in colorectal cancer effort

COPENHAGEN, Denmark--Boehringer’s looking to break into new markets with lung cancer med Vargatef (nintedanib). But in a Phase III study of patients with metastatic colorectal cancer, it came up just one-for-two on primary endpoints.

The med, when paired with best supportive care, improved progression-free survival in previously treated patients by 42%, Boehringer announced at the ESMO 2016 Congress. But that benefit didn’t translate into an improvement in overall survival. 

Now, Boehringer is analyzing the data to better understand the outcome, lead study investigator Eric Van Cutsem said in a statement. “While the outcome of the ... trial is not what we had hoped for, we continue to learn and evolve our research strategy with every study result from our development program,” BI’s VP and global head of medicine for oncology, Medhi Shahidi, added in separate remarks.

On-Demand Webinar

Leveraging A Medical Record-Enriched Patient Dataset for COVID-19 Research

You are invited to join a webinar that will explore the ways researchers can leverage this enriched dataset for important COVID-19 research. Sign up today for this informative webinar to learn how you can leverage one of the only medical record reviews solely using real-world data from hospitalized COVID-19 patients.

Right now, Vargatef is approved in the EU, in combination with docetaxel, as a treatment for some non-small cell lung cancer patients who've failed first-line chemo. But Boehringer is aiming to build on that indication, and to do so, it’s testing the product in other cancers, including malignant pleural mesothelioma.

Of course, nintedanib isn’t just a cancer drug. Back in October of 2014, the FDA approved it as Ofev, a therapy to treat deadly lung disease idiopathic pulmonary fibrosis.

But U.S. regulators didn’t approve Ofev alone. They also green-lighted Roche’s Esbriet on the very same day, setting up a head-to-head battle for U.S. market share. 

Related Articles:
Boehringer's Ofev, chasing a Roche rival, wins backing from NICE
Obstacles aside, Boehringer sees class-topping prospects for Ofev, Spiolto
Boehringer revs up Ofev sales force, support services to rival Roche's Esbriet in IPF
Same-day approvals send Roche, Boehringer to IPF market battle

Suggested Articles

Life sciences companies have pivoted quickly during COVID-19 - Syneos Health® is supporting more than 80 active COVID-19 projects, including vaccines.

New York's Covaxx has signed on with three South American nations to provide 140 million doses of its early-stage COVID-19 vaccine.

To get the COVID-19 vaccine out quickly, Pfizer has been running rehearsals at distribution sites, creating "growing confidence," U.S. officials said.